Poltreg S.A. Logo

Poltreg S.A.

A clinical-stage biotech developing T-regulatory cell therapies for autoimmune diseases.

PTG | WAR

Overview

Corporate Details

ISIN(s):
PLPLTRG00012 (+2 more)
LEI:
259400XSAJTERJ42VZ86
Country:
Poland
Address:
GDAŃSK BOTANICZNA 20, 80-298 GDAŃSK

Description

Poltreg S.A. is a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases. The company specializes in treatments based on T-regulatory cells (Tregs), with an advanced pipeline of both polyclonal and engineered cell therapies. Its lead product, PTG-007, is an autologous Treg treatment being investigated for Type 1 Diabetes and Multiple Sclerosis. Poltreg is also advancing next-generation engineered therapies, including Chimeric Antigen Receptor T-regulatory cells (CAR-Tregs), for neuroinflammatory conditions such as Multiple Sclerosis and Amyotrophic Lateral Sclerosis (ALS). The company operates its own state-of-the-art, cGMP-certified manufacturing facility to produce its advanced therapy medicinal products.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-04-16 17:42
Zwołanie Zwyczajnego Walnego Zgromadzenia PolTREG S.A. na dzień 20 maja 2025 r.…
Polish HTML 812 bytes
2025-04-16 17:24
Raport Roczny 2024
Polish ZIP 47.4 MB
2025-03-27 15:37
Nawiązanie współpracy z Noble Capital Markets Inc. dotyczącej przygotowania Spó…
Polish HTML 2.6 KB
2025-03-21 09:20
Nawiązanie strategicznej współpracy z firmą Antion Biosciences w celu rozwoju n…
Polish HTML 2.6 KB
2025-03-21 09:20
Nawiązanie strategicznej współpracy z firmą Antion Biosciences w celu rozwoju n…
Polish HTML 2.5 KB
2025-03-20 16:48
Warunkowe przyznanie patentu przez Kanadyjski Urząd Patentowy w projekcie terap…
Polish HTML 1.3 KB
2025-03-20 16:48
Warunkowe przyznanie patentu przez Kanadyjski Urząd Patentowy w projekcie terap…
Polish HTML 1.3 KB
2025-02-24 12:17
Zawarcie umowy na doradztwo strategiczne ws. rejestracji terapii TREGS w Stanac…
Polish HTML 1.7 KB
2025-02-24 12:17
Zawarcie umowy na doradztwo strategiczne ws. rejestracji terapii TREGS w Stanac…
Polish HTML 1.7 KB
2025-02-07 20:51
Informacja nt. rekomendowania przez Agencję Badań Medycznych dofinansowania pr…
Polish HTML 1.3 KB
2025-02-06 20:51
Informacja nt. rekomendowania przez Agencję Badań Medycznych dofinansowania pr…
Polish HTML 1.3 KB
2025-01-24 14:37
Harmonogram publikacji raportów okresowych w 2025 roku - Content (PL)
Polish HTML 864 bytes
2025-01-20 21:02
Informacja nt. rekomendowania przez Polską Agencję Rozwoju Przedsiębiorczości d…
Polish HTML 1.6 KB
2025-01-20 17:30
Rezygnacja z funkcji Członka Zarządu PolTREG S.A. - Content (PL)
Polish HTML 717 bytes
2025-01-08 16:06
Warunkowe przyznanie patentu przez Japoński Urząd Patentowy dotyczącego procesu…
Polish HTML 808 bytes

Automate Your Workflow. Get a real-time feed of all Poltreg S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Poltreg S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Poltreg S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.